BRCA2 and breast carcinoma: Next, the in vivo efficacy of RTx-303 was evaluatedat 60 mg/kg(po, bid) as a single agent and in combination with olaparib againsta BRCA2 mutant breast cancer PDX model (BR-05–0566)in BALB/c mice.